The Supreme Court on Monday temporarily blocked a lower-court order that would have stopped the abortion pill mifepristone from being shipped through the mail, keeping the FDA’s current rules in place while the legal battle continues.
Justice Samuel Alito issued an administrative stay that pauses a Friday decision from the 5th U.S. Circuit Court of Appeals. The stay is set to run until at least 5 p.m. ET on May 11, though the justices could extend it depending on what happens next in the case.
Alito also gave Louisiana until 5 p.m. Thursday to respond to emergency requests asking the Supreme Court to keep the 5th Circuit’s restriction on ice while litigation plays out. That response window sets up the next checkpoint in the fast-moving fight over how mifepristone can be distributed nationwide.
The case traces back to Louisiana’s lawsuit against the Food and Drug Administration over the agency’s 2023 decision to lift an older rule requiring mifepristone to be dispensed in person. By removing that in-person requirement, the FDA allowed the drug to be distributed through the mail, a shift that expanded access and became a major flashpoint in the post-Roe abortion landscape.
Two drugmakers, Danco Laboratories and GenBioPro, asked the Supreme Court over the weekend to block the 5th Circuit’s ruling and preserve mail delivery while the case moves forward. Their argument, in essence, is that the 5th Circuit’s order would abruptly disrupt distribution of a drug that has been widely used and regulated at the federal level for years, creating confusion for patients and providers as courts continue to wrestle with the dispute.
Mifepristone is typically used with a second drug in a two-step medication abortion regimen and is used in about two-thirds of abortions in the United States, according to reports. That makes any change in access a high-stakes development, not just legally but practically, because it can immediately affect how abortion services are provided in many states.
Monday’s order does not decide the underlying question of whether the FDA acted lawfully in changing its distribution rules. An administrative stay is a procedural pause. It is designed to prevent a major shift from taking effect before the court has time to review emergency filings and decide whether longer-term relief is warranted.
The timeline now turns to Louisiana’s Thursday deadline. After the state responds, the Supreme Court could let the temporary pause expire on May 11, extend it, or issue a different form of emergency order that stays the 5th Circuit’s ruling for longer while the appeal continues. In other words, the legal temperature is not dropping, but the immediate brakes are on.
For the moment, the Supreme Court’s move keeps mifepristone available for mail delivery under the FDA’s current framework while the parties fight over who gets to set the rules, and how far courts can go in second-guessing federal drug regulators.
Download the FREE Trending Politics App to get the latest news FIRST >>
